Hikma Pharmaceuticals Regulatory News (HIK)

Hikma Pharmaceuticals PLC - Share Transactions

LONDON, 9 November 2010: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK), in accordance with DTR 3.1.2R and s.793 of the Companies Act 2006, announces that Dr. Ronald Goode, a non-executive Director, has undertaken transactions in the Company's Ordinary Shares of 10p each. The transactions took place in London as detailed below.

On 1 November 2010, Dr Goode acquired 3,700 Ordinary Shares of 10p each, representing 0.002 per cent. of the issued share capital of the Company, at an average price of $12.89 cents per Ordinary Share.

The Company was notified of this transaction on 8 November 2010 after the market close.

Following these transactions Dr. Goode holds 9,700 ordinary shares, representing 0.005 per cent. of the issued share capital of the Company.

- ENDS -

Enquiries:

Hikma Pharmaceuticals PLC

Henry Knowles +44 20 7399 2760

Company Secretary

Susan Ringdal +44 20 7399 2760

Investor Relations Director

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2009, Hikma achieved revenues of $637 million and profit attributable to shareholders of $78 million. For news and other information, please visit www.hikma.com.